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Interferon- (IFN-), a proinflammatory cytokine,
has been implicated in the pathogenesis of a number
of forms of heart disease including myocarditis and
congestive heart failure. In fact, overexpression of
IFN- in mice causes dilated cardiomyopathy. How-
ever, the direct effects of IFN- on cardiac myocytes
and the mechanism by which it causes cardiac dysfunc-
tion have not been described. Here, we present the mo-
lecular pathology of IFN- exposure and its effect on
myofibrillar proteins in isolated neonatal rat ventricu-
larmyocytes. Treatment with IFN- caused cardiacmyo-
cyte atrophy attributable to a specific decrease in myo-
sin heavy chain protein. This selective degradation of
myosin heavy chainwas not accompanied by a decrease
in total protein synthesis or by an increase in total
protein degradation. IFN- increased both proteasome
and immunoproteasome activity in cardiac myocytes
and their inhibition blocked myosin heavy chain loss
and myocyte atrophy, whereas inhibition of the lyso-
some or autophagosome did not. Collectively, these re-
sults provide a mechanism by which IFN- causes car-
diac pathology in the setting of chronic inflammatory
diseases. (Am J Pathol 2012, 181:2038–2046; http://dx.doi.
org/10.1016/j.ajpath.2012.08.040)
Both infectious and noninfectious agents including vi-
ruses, parasites, and some chemotherapeutic drugs can
elicit a significant immune response in the heart. The
resulting inflammation, which can persist long after reso-
lution of the cardiac insult, causes myocarditis and is
implicated in approximately 20% of sudden deaths in
children and young adults.1 The most common cause
of myocarditis worldwide is the parasitic protozoan
Trypanosoma cruzi, which causes Chagas disease and is
2038the leading cause of congestive heart failure in South
America.2 Approximately 80% of patients with Chagas
disease develop cardiac complications and 20% require
heart transplantation.3 Coxsackievirus type B3, HIV, and
adenovirus are the predominant causes of myocarditis in
developed countries.4 Through direct infection of cardiac
tissue and a subsequent persistent inflammatory re-
sponse in the heart, a subset of these patients will de-
velop chronic myocarditis, which is characterized by fi-
brosis and myocyte atrophy, and, ultimately, can lead to
dilated cardiomyopathy (DCM).5,6 Approximately 50% of
patients with DCM die within 2 years of diagnosis.7 In one
study of asymptomatic HIV-positive patients, for exam-
ple, 80% had DCM, with most (83%) showing concomi-
tant myocarditis.4,8–10 Myocarditis therefore is associ-
ated with many different diseases, yet often is overlooked
clinically, likely owing to its asymptomatic course in most
patients and its association with cardiomyopathies.
In cardiac infection, natural killer cells and macro-
phages infiltrate the myocardium and promote recruit-
ment of T lymphocytes, which induces a robust local
increase in proinflammatory cytokine production. Interfer-
on- (IFN-), the predominant inflammatory cytokine in
myocarditis, is up-regulated significantly in the myocar-
dium of patients with Chagas disease2 and is implicated
in the pathogenesis of myocarditis.11 During infection,
IFN- up-regulates expression of major histocompatibility
complexes I and II on infected and uninfected cells, thus
enhancing the diversity of peptides displayed on these
cells.12 Inflammation that is associated with up-regulation
of IFN- and other cytokines often persists in patients for
months or years after the clearance of infection. Although
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the development of DCM and heart failure in some pa-
tients.13 However, the mechanism by which inflammation
causes DCM and heart failure is not well understood.
A causative cytotoxic role for IFN- is supported by
studies in mice: constitutive overexpression of IFN- in
the liver, which increases serum IFN- levels, causes
cardiac myofiber atrophy and DCM, similar to that which
develops in some patients with myocarditis.14,15 Interest-
ingly, systemic overexpression of IFN- only affected the
heart and did not affect skeletal or smooth muscle. How-
ever, the direct effects of IFN- on cardiac myocytes
were not determined. Here, we examine the effects of
IFN- on cardiac myocytes in isolation from the compli-
cated systemic and local effects of infection and suggest
a mechanism for the specificity of cytotoxicity in the heart.
Materials and Methods
Cell Culture
Animal use was in accordance with protocols approved
by the Institutional Animal Care and Use Committee at the
University of Colorado at Boulder and conformed with
guidelines published by the US NIH. Neonatal rat ven-
tricular myocytes (NRVMs) were isolated and cultured as
previously described.16 Approximately 50 to 75 hearts
were pooled per preparation. Each experiment was per-
formed in triplicate and then repeated at least two times,
each with distinct NRVM populations. After an 18-hour
recovery period, cells were treated with PBS and 0.2 or
200 U/mL mouse recombinant IFN- (Calbiochem/EMD
Chemicals, Gibbstown, NJ) for 24 or 48 hours. These
doses were chosen to be physiologic and supraphysi-
ologic, respectively. The supraphysiologic dose is simi-
lar to those used by others to study the in vitro effect of
IFN- on cardiomyocytes.17–19 Proteasome activity was
blocked pharmacologically by treating cells with 1
mol/L MG-132 (Boston Biochem, Cambridge, MA) or 5
nmol/L bortezomib (Millennium Pharmaceuticals, Cam-
bridge, MA) for 48 hours. To inhibit lysosome activity,
cells were treated with 10 mmol/L NH4Cl (Sigma, St.
Louis, MO) or 2.5 mmol/L 3-methyladenine (Sigma).
NRVMs also were treated with 100 nmol/L or 10 mol/L
dexamethasone or 20 ng/mL tumor necrosis factor 
(TNF-) for 48 hours in parallel experiments.
Immunocytochemistry and Cell Area
Measurement
NRVMs cultured on coverslips were fixed in 4% parafor-
maldehyde for 20 minutes, permeabilized with 0.1% Tri-
ton X-100 (Fisher Scientific, Pittsburgh, PA), blocked with
10% horse serum, and incubated overnight at 4°C with
anti–-actinin antibodies (1:200; Sigma). Cells then were
incubated with appropriate fluorophore-conjugated sec-
ondary antibodies for 30 minutes at room temperature
and visualized using fluorescence microscopy. Digitized
images of cells (three fields in triplicate, 60 to 80 cells
total per condition) were obtained and the cell area wasmeasured using ImageJ software version 1.43t (NIH, Be-
thesda, MD).
Cell Volume Measurement
After 48 hours of IFN- treatment, NRVMs were try-
psinized and suspended in PBS containing 1% bovine
calf serum and 10 mmol/L EDTA. The cell volume per
sample was measured in a Coulter Counter Analyzer
(Beckman Coulter, Brea, CA). Each sample was ana-
lyzed in triplicate and experiments were repeated twice.
Average volumes were calculated for each treatment
group and values were normalized to vehicle-treated
myocytes.
Myofibrillar Gels and Western Blots
For myosin heavy chain (MyHC) analysis, NRVMs were
lysed in high-salt myosin extraction buffer.20 Lysates
were centrifuged at 13,500 g for 15 minutes at 4°C. The
supernatant was removed and protein concentration was
determined using a detergent-compatible protein assay
(Bio-Rad Laboratories, Hercules, CA). Protein (2.5 g per
sample) was loaded onto myofibrillar gels, which were
composed of 15% acrylamide (124:1 acrylamide: bis),
9.79% glycerol, 0.73 mol/L Tris pH 9.3, and 0.1% SDS.
Gels were run at 16 mA for 6 hours at 4°C, silver stained
(Bio-Rad Silver Stain Plus; Bio-Rad Laboratories), and
digitally scanned. Antibodies for immunoblots were as
follows: anti–-MyHC (BA-G5 hybridoma, 1:5; ATCC, Ma-
nassas, VA), anti–-MyHC (1:400; Vector Laboratories,
Burlingame, CA), and anti–light chain 3b (1:1000; Cell
Signaling, Boston, MA). Immunoreactivity was visualized
using an enhanced chemiluminescence detection sys-
tem (Perkin Elmer, Waltham, MA) and band intensities
were quantified using ImageJ software.21
RNA Analysis
Total RNA was isolated from NRVM cultures using a TRI-
zol-based reagent (Molecular Research Center, Inc., Cin-
cinnati, OH). First-strand cDNA was synthesized using
reverse transcriptase (Invitrogen, Carlsbad, CA) and ran-
dom hexamer primers. Gene expression then was mea-
sured using quantitative real-time polymerase chain re-
action (qPCR) using a 7500 Real-Time PCR system
(Applied Biosystems, Carlsbad, CA). Primer sequences
were as follows: atrogin-1 forward, 5=-GAACATCATGCA-
GAGGCTGA-3= and reverse, 5=-CGAGTCACTTCTGGC-
CGATG-3=; and muscle ring finger protein 1 (MuRF-1)
forward, 5=-GTGAGGTTGCCCCTTTGCAA-3= and re-
verse, 5=-CGACTCATTGACGTAGAGGT-3=.
Caspase and Proteasome Activity Assays
Caspase-3 activity in cardiac lysates was determined by
monitoring the rate of cleavage of a synthetic fluoroge-
nic caspase-3–specific substrate (Ac-Asp-Glu-Val-Asp-
AMC; Calbiochem/EMD Chemicals) as previously de-
scribed.22 Proteasome activity was determined as de-
2040 Cosper et al
AJP December 2012, Vol. 181, No. 6scribed,23 except ATP was not added to the reaction
mixture because optimization of conditions revealed that
the addition of ATP significantly decreased activity. Ac-
tivity was determined using 15 g protein and 20 mol/L
fluorogenic substrate [proteasome: Suc-LLVY-AMC (Bos-
ton Biochem) or immunoproteasome: Ac-PAL-AMC (a gift
from Millennium Pharmaceuticals, Inc.)]. To ensure spec-
ificity of the assay, 5 nmol/L bortezomib (a gift from Mil-
lennium Pharmaceuticals, Inc.), which more specifically
and potently inhibits proteasomes, was used in parallel
experiments.24 Fluorescent emission resulting from
cleavage of the appropriate substrate was recorded ev-
ery 2 minutes for 1 hour at 37°C using a Synergy 2
multimode microplate reader (BioTek, Winooski, VT). Pro-
teasome activity was calculated as the slope of the linear
portion of the line produced by emission of cleaved sub-
strate over time for each sample normalized to protein
concentration.
Pulse and Pulse-Chase Assays
To evaluate protein synthesis, NRVMs were treated with
200 U/mL IFN- for 46 hours. Cells were washed and
incubated with [3H]-tyrosine and IFN- for 2 hours. Cells
were collected in 10% trichloroacetic acid and the incor-
porated radioactivity was determined using a scintillation
counter. Protein synthesis is represented as the number
of counts normalized to protein concentration per well.
Protein degradation rates in NRVMs were determined as
previously described,25 with modification; after the initial
24-hour incubation period with [3H]-tyrosine, cells were
treated with IFN- for 24 hours in medium containing 2
mmol/L unlabeled tyrosine to prevent reincorporation of
radiolabeled tyrosine. In some experiments, cells also
were treated with either proteasome (1 mol/L MG-132)
or lysosomal (10 mmol/L NH4Cl) inhibitors for 2 hours
before collecting media samples. For autoradiography
experiments, cells were incubated for 24 hours with [35S]-
methionine and then treated with IFN- for 24 hours in the
presence of 2 mmol/L unlabeled methionine. Cellular pro-
teins were extracted in myosin extraction buffer, and run
on myofibrillar gels as described earlier. Gels were dried
and digitally scanned autoradiograms were analyzed
densitometrically using ImageJ software. All experiments
were performed three times and measurements were
performed in triplicate.
Figure 1. IFN- induces atrophy of NRVMs. A: Representative images of N
against -actinin. B: Quantification of myocyte area after treatment with vehicle or IFN
***P  0.001 compared with control.Data and Statistical Analysis
Data are presented as means  SEM calculated from
averages obtained from at least three NRVM isolations.
Differences between groups were evaluated for statistical
significance using the Student’s t-tests. P values less
than 0.05 were considered significant.
Results
IFN- Causes Myocyte Atrophy and a Specific
Decrease in Cardiac MyHC in Vitro
Transgenic mice with constitutively increased levels of
circulating IFN- show chronic myocarditis with signifi-
cant cardiac myofiber atrophy14 consistent with cardiac
pathology observed in a subset of patients with myocar-
ditis.6 To determine whether this phenotype occurs in
cardiac myocytes in culture, NRVMs were treated with
200 U/mL IFN- for 48 hours. NRVMs were used to isolate
the direct effects of IFN- on cardiomyocytes without the
complicated immune responses to systemic infection.
NRVMs are a well-described model system because they
respond similarly to intact hearts to many hypertrophic
agonists and cardiotoxic agents.26–28 They also can be
efficiently infected with viruses or viral particles that are
implicated in myocarditis and respond to the cytokines
that are up-regulated during these infections.26 The pre-
dominant morphologic effect of IFN- on NRVMs was a
qualitative reduction in myocyte size (Figure 1A). Quan-
tification revealed that treatment with IFN- caused a
significant decrease in myocyte area (reduced by 26%
2%) (Figure 1B) and volume (reduced by 9%  1.5%)
(Figure 1C).
We hypothesized that the reduction in cell size in re-
sponse to IFN- is attributable to a decrease in MyHC,
the most abundant sarcomeric protein in cardiac muscle
by mass.29 NRVMs were treated with IFN- or vehicle,
and MyHC was solubilized and resolved on myofibrillar
gels. Treatment with IFN- caused a decrease in total
MyHC by 40%  13% at 24 hours and 58%  6% at 48
hours (Figure 2A) compared with untreated controls at
the respective time points. This effect also was observed
at a lower physiological concentration of IFN- (0.2 U/mL)
(Figure 2B).
ated with vehicle (control) or IFN- immunolabeled with antibodies raisedRVMs tre
-. C: Quantification of NRVM volume after treatment with vehicle or IFN-.
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in NRVMs, we determined the effect of IFN- on the two
MyHC isoforms in cardiac muscle: -MyHC and -MyHC.
Unlike adult rodent hearts, in which -MyHC predomi-
nantly is expressed, equal amounts of -MyHC and
-MyHC are expressed in NRVMs.30 Western blots for the
two cardiac MyHC isoforms revealed an equivalent de-
Figure 2. IFN- induces a specific decrease in MyHC protein. A: Top panel:
Representative myofibrillar gel of protein lysates obtained from NRVMs
treated with vehicle (control lanes) or 200 U/mL IFN- for 24 or 48 hours.
Bottom panel: Densitometric quantification of MyHC band intensities, nor-
malized to vehicle-treated cells. B: Top panel: Representative myofibrillar
gel of protein lysates treated with vehicle (control lane) or 0.2 U/mL IFN- for
24 hours. Bottom panel: Densitometric quantification of MyHC band inten-
sities, normalized to vehicle-treated cells. C: Representative Western blots
using antibodies raised against -MyHC and -MyHC in NRVMs treated with
vehicle or IFN-. D: Quantification of -MyHC and -MyHC gene expression
in NRVMs treated with IFN- for 24 or 48 hours. E: Representative myofibril-
lar gel of protein lysates obtained from NRVMs treated with vehicle or IFN-.
Bands representing sarcomeric proteins are as indicated. MyLC, myosin light
chain. F: Caspase activity in NRVMs treated with vehicle, IFN-, or 1 mol/L
Staurosporine (Stauro) for 48 hours. The rate of caspase activity was normal-
ized to the concentration of protein in each sample (n  2 preparations). G:
Representative Western blot using antibodies raised against cardiac MyHC in
NRVMs treated with IFN-, TNF-, dexamethasone, or vehicle. Samples are
on the same gel but the last four lanes are noncontiguous. *P  0.05, **P 
0.01, and ***P  0.001 compared with control.crease in both -MyHC and -MyHC protein at 48 hours(Figure 2C). We concluded that this decrease in MyHC is
mediated posttranscriptionally because -MyHC and
-MyHC mRNA levels did not decrease significantly with
IFN- treatment compared with vehicle-treated NRVMs
(Figure 2D). Interestingly, mRNA levels of -MyHC actu-
ally increased after 24 hours of treatment. These data
suggest that the mechanism by which IFN- induces
atrophy is distinct from that of other cytokines that are
up-regulated with cancer and cause repression of sarco-
meric mRNA levels.31
To extend our analyses to other myofibrillar proteins
that comprise the sarcomere, we analyzed the myofibril-
lar fractions of vehicle- and IFN--treated NRVMs. SDS-
PAGE gels revealed that despite the decrease in MyHC,
all nonmyosin myofibrillar proteins (myosin binding pro-
tein, actin, troponin, tropomyosin, and myosin light chains
1 and 2) were unaffected (Figure 2E). Myosin-to-actin
ratios therefore were decreased consistently (51.5% 
3.6%) whereas all other myofibrillar protein ratios did not
significantly change, indicating a possible protein-spe-
cific catabolic mechanism by which atrophy occurs.
Although IFN- treatment has not been associated pre-
viously with reduced myocyte viability and the hearts of
patients with chronic myocarditis do not show markers for
apoptosis,32 we measured the activity of caspase-3 to
test whether reduced MyHC is the result of cell death in
our system. As expected, IFN- did not activate
caspase-3 activity in NRVMs (Figure 2F). Thus, IFN-
treatment caused both NRVM atrophy and a specific
decrease in MyHC protein through a mechanism inde-
pendent of apoptosis.
Increased levels of circulating cytokines and glucocor-
ticoids observed in some chronic disease states are as-
sociated with significant skeletal or cardiac muscle atro-
phy and degradation of myofibrillar proteins through
mechanisms that are not well understood.33,34 To deter-
mine whether the selective decrease in MyHC induced
by IFN- in NRVMs is restricted to this cytokine, we
treated cells with TNF-35 or dexamethasone,36 which
have been shown to induce muscle atrophy.35,36 Neither
treatment caused a decrease in MyHC in NRVMs (Figure
2G). In addition, treatment with both TNF- and IFN- did
not increase MyHC loss greater than that observed with
IFN- alone.
Cardiac Myocyte Atrophy Is Attributable to the
Selective Degradation of MyHC
Myocyte atrophy may be attributable to decreased pro-
tein synthesis, an increase in protein degradation, or
both. We first performed a pulse assay with [3H]-tyrosine
to measure changes in total protein synthesis in the pres-
ence of IFN-. NRVMs were harvested after 48 hours of
exposure to IFN- and 2 hours after incorporation of
[3H]-tyrosine, which was quantified and represented the
extent of protein synthesis. Total protein synthesis was
unaffected by 48-hour IFN- treatment (Figure 3A). To
examine whether increased protein degradation is re-
sponsible for the decrease in myocyte size, cardiac myo-
cyte proteins were radiolabeled with [3H]-tyrosine and
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tyrosine to prevent reincorporation. The extent of protein
degradation was quantified by measuring [3H]-tyrosine in
the medium 24 hours after IFN- treatment. There was no
change in total protein degradation rates compared with
vehicle-treated cells (Figure 3B).
To increase the sensitivity of our study, NRVM proteins
were radiolabeled with [35S]-methionine for 24 hours and
then treated for 24 hours with IFN- in media containing
excess unlabeled methionine. Similar to [3H]-tyrosine,
[35S]-methionine becomes incorporated into newly syn-
thesized proteins but has the advantage of allowing
efficient visualization of these proteins on a gel using
autoradiography. Labeled cell extracts run on myofi-
brillar gels revealed, once again, that MyHC is de-
Figure 3. IFN- induces a specific decrease in MyHC without altering total
protein synthesis or degradation. A: Quantification of total protein synthesis
measured using [3H]-tyrosine pulse assay in NRVMs treated with vehicle
(control) or IFN-. CPM, count per minute. B: Quantification of protein
degradation by measuring [3H]-tyrosine released in the media 24 hours after
vehicle, IFN-, NH4Cl, or MG-132 treatment. C:Myofibrillar autoradiogram of
NRVM proteins pulse labeled with [35S]-methionine and treated with vehicle
or IFN-. MyHC and actin bands are as indicated. D: Quantification of MyHC
and actin band intensities (C) expressed as a ratio, normalized to vehicle-
treated cells. ***P  0.001 compared with control.creased selectively in the IFN-–treated myocytes (Fig-
ure 3C). IFN- induced a 48%  8% reduction in the
MyHC-to-actin ratio (Figure 3D). These data do not
support a mechanism involving alterations in total pro-
tein turnover, unlike other models of cardiac atrophy.37
We therefore performed a series of experiments to
examine the proteolytic mechanisms that mediate the
specific degradation of MyHC.
The Lysosome Does Not Contribute to
IFN-–Induced MyHC Degradation
Several proteolytic mechanisms are responsible for reg-
ulating the degradation of the sarcomere in cardiac myo-
cytes, namely the lysosomal and proteasomal pathways.
We previously showed that the autophagosomal-lyso-
somal pathway is up-regulated in the atrophic hearts of
tumor-bearing mice that have high circulating levels of
proinflammatory cytokines.38 We first sought to deter-
mine the relative contributions of the lysosomal and ubiq-
uitin proteasome pathways on basal levels of protein
degradation in control and IFN-–treated NRVMs. We
performed a pulse-chase assay as described earlier and
treated cells with a lysosome inhibitor (NH4Cl) or protea-
some inhibitor (MG-132). Inhibiting the lysosome in con-
trol cells reduced total protein degradation by 31% 
2.1% (Figures 3B and 4A), whereas inhibiting the protea-
some reduced total protein degradation by 72%  1.4%
(Figures 3B and 5B), confirming their relative contribution
to basal levels of protein degradation. As mentioned pre-
viously, treatment with IFN- did not affect total protein
degradation rates or the relative contributions of each
degradative pathway (Figure 3B).
To further examine the role of the lysosomal pathway,
we co-treated NRVMs with NH4Cl and IFN- and ana-
lyzed the levels of MyHC and other sarcomeric proteins.
Although inhibition of the lysosome in cardiac myocytes
reduced proteolysis (Figure 4A), it did not prevent MyHC
Figure 4. IFN-–induced specific degradation of
MyHC is not attributable to the lysosome-autopha-
gosome pathway. A: Quantification of proteolytic
activity after inhibition of lysosome in NRVMs
treated with vehicle (control) or lysosome inhibi-
tor (NH4Cl), normalized to vehicle-treated NRVMs.
B: Left panel: Representative myofibrillar gel of
protein lysates from NRVMs treated with lysosome
inhibitor (NH4Cl) and vehicle or IFN-. MyHC
band is as indicated. Right panel: Densitometric
quantification of MyHC band intensities, normal-
ized to vehicle-treated cells. C: Representative
Western blot using antibodies raised against light
chain 3 (LC3)-II, a marker of autophagosome ac-
tivity, or glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) on lysates from NRVMs treated
with vehicle, IFN-, IFN- plus an autophagosome
inhibitor [3-methyladenine (3-MA)], or rapamycin
(Rap). D: Left panel: Representative myofibrillar
gel of protein lysates from NRVMs treated with
3-MA and vehicle or IFN-. MyHC band is as in-
dicated. Right panel: Densitometric quantifica-
tion of MyHC band intensities normalized to vehi-
cle-treated cells. ***P  0.001 compared with
control.
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lysosome is not involved in MyHC degradation in this
model, but rather is involved in basal levels of protein
turnover required to maintain cardiac myocyte func-
tion.39 To determine whether components of the auto-
phagosomal pathway are up-regulated during cardiac
myocyte atrophy, we quantified the levels of microtubule-
associated light chain 3 II, a protein specifically localized
to autophagic vacuoles and a marker of increased au-
tophagic activity.40 These experiments revealed that
IFN- did not increase light chain 3 II levels (Figure 4C),
whereas rapamycin, a known inducer of autophagy, did.
To examine autophagosomal activity in our model more
directly, autophagy was inhibited with 3-methyladenine,
which blocks autophagosome formation.41 Co-treatment
with IFN- and 3-methyladenine did not affect light chain
3 II levels or reduce MyHC degradation induced by IFN-
Figure 5. The proteasome is responsible for IFN-–induced degradation of
MyHC in NRVMs. A: Proteasome activity in NRVMs treated with vehicle
(control), IFN-, or bortezomib for 24 or 48 hours. Bars are normalized to
control at each time point. B: Quantification of proteolytic activity after
inhibition of the proteasome in NRVMs treated with MG-132 or vehicle,
normalized to vehicle-treated NRVMs. C: Top panel: Representative myofi-
brillar gels of protein lysates from NRVMs treated with vehicle (C) or IFN-
and vehicle (dimethyl sulfoxide, DMSO) or MG-132. The MyHC band is as
indicated. Bottom panel: Densitometric quantification of MyHC. Values are
normalized to vehicle-treated cells. D: Top panel: Representative images of
NRVMs treated with vehicle or IFN- in the presence or absence of bort-
ezomib. Cells were immunolabeled with antibodies raised against -actinin.
Bottom panel: Quantification of the NRVM area, indicated as arbitrary units.
E: Immunoproteasome activity in NRVMs treated with vehicle (control),
IFN-, or bortezomib for 24 or 48 hours. Bars are normalized to control at
each time point. F: Quantification of expression of atrogin-1 or MuRF-1
normalized to 18S in NRVMs treated with IFN- for 24 or 48 hours. All values
are normalized to expression in vehicle-treated myocytes. *P  0.05, **P 
0.01, and ***P  0.001 compared with control or as indicated. †P  0.001
compared with the respective no drug samples.alone (Figure 4, C and D). Taken together, these resultsshow that the autophagosomal-lysosomal pathway is not
involved in IFN-–induced cardiac MyHC degradation in
NRVMs.
IFN- Causes Cardiac MyHC Degradation by
the Ubiquitin Proteasome System and an
Increase in Immunoproteasome Activity in Vitro
The ubiquitin proteasome system (UPS) is primarily re-
sponsible for protein turnover in the heart and is neces-
sary for the maintenance of sarcomeric stoichiometry.42
The UPS also is responsible for mediating detrimental
cardiac effects in other chronic diseases with high levels
of circulating inflammatory cytokines.43 Because we
found that the UPS is the primary proteolytic pathway
active in NRVMs, we performed a fluorometric protea-
some activity assay to examine the role of the UPS in
IFN-–induced myocyte atrophy. A time-dependent in-
crease in UPS activity after 24 and 48 hours of IFN-
treatment was observed (1.6-fold higher and 2.4-fold
higher activity, respectively) (Figure 5A). To measure
basal protein degradation and confirm the role of the UPS
in untreated myocytes, NRVMs were treated with MG-
132. As mentioned earlier, proteolysis was reduced sig-
nificantly by inhibition of the proteasome (72% reduction
in total protein degradation compared with untreated
cells) (Figures 3B and 5B). To determine whether protea-
some inhibition prevents MyHC degradation, NRVMs
were co-treated with IFN- and MG-132. MG-132 treat-
ment completely prevented MyHC loss in IFN-–treated
NRVMs and increased MyHC levels slightly above that of
control myocytes (16% 6%)(Figure 5C). Treatment with
bortezomib, a more potent and specific inhibitor of chy-
motrypsin activity of the proteasome,24 also fully pre-
vented the degradation of MyHC in IFN-–treated cells
(Figure 5C), supporting the conclusion that the protea-
some is involved in IFN-–mediated MyHC degradation.
To determine whether proteasome inhibition prevents
IFN-–induced myocyte atrophy, cross-sectional area
was measured after 48 hours of IFN- treatment with or
without bortezomib. Bortezomib treatment prevented
myocyte atrophy and caused a significant increase in
myocyte size over control values (Figure 5D). Inhibition of
the UPS with bortezomib causes a significant increase in
cellular protein, which recently was shown to manifest as
cellular hypertrophy.44,45
Viral infection up-regulates a second type of protea-
some, the immunoproteasome.46 The inner proteolytic
core of the proteasome is composed of two rings of
-subunits that contain chymotryptic, tryptic, and
caspase-like activity.47 IFN- causes the replacement of
three of these -subunits with corresponding immuno-
forms: LMP2, LMP7, and MECL-1.48 The incorporation of
these inducible subunits collectively forms the immuno-
proteasome, which favors formation of peptide fragments
for display on major histocompatibility complexes during
an immune response. Indeed, coxsackievirus type B3–
infected mice that have high levels of IFN- in the heart
show significant up-regulation of immunoproteasome in
cardiac tissue.49 Our previous studies on proteasome
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inducible immunoproteasome. We therefore measured
immunoproteasome activity to delineate these pro-
cesses. By using a substrate that has 10-fold higher
specificity for the immunoproteasome over the protea-
some, we found a 2.7-fold increase after 24 hours of
IFN- treatment and a striking eightfold increase in im-
munoproteasome activity after 48 hours (Figure 5E), sug-
gesting that the immunoproteasome plays a primary role
in IFN-–induced MyHC degradation and atrophy in
NRVMs.
To further probe the proteasome pathway, we quanti-
fied the expression of atrogin-1 and MuRF-1, which are
muscle-specific E3-ubiquitin ligases that mark specific
substrates for degradation by the proteasome and are
transcriptionally up-regulated during skeletal muscle at-
rophy.50 Atrogin-1 and MuRF-1 mRNA levels in cardiac
myocytes were measured after 24 and 48 hours of IFN-
treatment, but neither gene was induced at any time point
(Figure 5F). Our data suggest that these E3 ligases are
not involved in IFN-–induced MyHC degradation, which
is consistent with our findings in atrophic mouse hearts.38
However, the levels of atrogin-1 and MuRF-1 transcripts
are approximately three times higher in heart than in
skeletal muscle,38 suggesting that basal levels of these
ligases may be sufficient for increased MyHC degrada-
tion induced by IFN-.
Discussion
Proinflammatory cytokines are up-regulated in re-
sponse to cardiotropic infections including those
caused by viruses and parasitic protozoans. Despite
clearance of the active infection by the immune sys-
tem, proinflammatory cytokines can persist in the heart
for months or years, leading to chronic myocarditis
and, in some cases, severe cardiomyopathy.6 Defining
the mechanism of the cytotoxic cardiac effects of IFN-
in animal models is complicated by the acute pathol-
ogy caused by active cardiotropic infection. Viral pro-
teins, for example, can induce myocyte damage di-
rectly by production of enzymes that are capable of
degrading cardiac myocyte proteins such as dystro-
phin.51,52 Mice with constitutively increased serum lev-
els of IFN-, one of the predominant cytokines in
chronic myocaditis, have cardiac dysfunction includ-
ing left venticular dilation and premature death, likely
caused by heart failure.14 However, a coincident in-
crease in serum TNF- complicates the interpretation
of these studies. We therefore sought to isolate the
effects of IFN- from the complicated immune re-
sponse that is mounted both during and after active
cardiotropic infection and from those of viral or proto-
zoan proteins.
The Specific Degradation of MyHC Mediates
IFN-–Induced Cardiac Myocyte Atrophy
Cardiac atrophy occurs in a transgenic murine model of
HIV infection, in rats infected with T. cruzi, and in miceoverexpressing IFN-.53,54 Our studies show that cardiac
myocyte atrophy induced by IFN- is caused by the
specific degradation of MyHC rather than a general deg-
radative process. Interestingly, myocyte atrophy oc-
curred without a loss of total protein or an increase in total
protein degradation, thus it is possible that the reduction
in cell size and volume could reflect a change in confor-
mation resulting from the loss of MyHC.
Interestingly, all other myofibrillar proteins studied
were unaffected. Selective degradation of myocyte
proteins has received relatively little attention as a
mechanism by which cardiac atrophy occurs. Impor-
tantly, this process occurs in the absence of immune
cell involvement and therefore does not require release
of TNF- from dendritic cells or macrophages, which
appears to be responsible at least in part for the car-
diac dysfunction observed when IFN- is overex-
pressed in mice.55 In addition, although TNF- and
IFN- are both required for MyHC loss in skeletal mus-
cle in vitro,31 we found that TNF- did not have any
effect on MyHC loss either alone or in combination with
IFN-, which implies that IFN- does not mediate its
effects through TNF- in this model.
The E3 ligases atrogin-1 and MuRF-1 were not up-
regulated in cardiomyocytes treated with IFN- despite
the role of the proteasome in the degradation of MyHC. In
addition to atrogin-1 and MuRF-1, other E3 ligases as well
as E2 ligases and protein modifications can direct the
specificity of the UPS.56 In diabetic cardiomyopathy, for
example, MuRF-1 and atrogin-1 are unchanged but the
C-terminus of HSC70 interacting protein ubiquitin ligase
regulates myocyte injury during hyperglycemia.57 In ad-
dition, because expression of MuRF-1 and atrogin-1 are
approximately threefold higher in cardiac muscle than in
skeletal muscle,38 it is possible that the baseline levels of
these ligases are sufficient to forgo the need for transcrip-
tional up-regulation.
Sarcomeric proteins have been thought to be insen-
sitive to degradation by the UPS because of limited
accessibility of the proteins by E3 ligases.58 However,
our data suggest that MyHC is degraded by the pro-
teasome without complete sarcomeric disintegration
because other myofibrillar proteins that are required for
sarcomere stability are not degraded. In addition, the
myofibrillar protein purification method used in these
studies isolates proteins incorporated into the sarcom-
ere rather than completely unincorporated or newly
synthesized MyHC that might be susceptible to target-
ing by E3 ligases.20 Interestingly, it recently was re-
ported that thick filament proteins such as myosin
binding protein-C and myosin light chain may be ubiq-
uitinated within the sarcomere.58 Other E3 ligases such
as Ozz also selectively recognize sarcomeric proteins,
such as MyHC, rather than unincorporated sarcomeric
proteins.59 These studies shed light on possible novel
mechanisms by which MyHC degradation occurs, with-
out up-regulation of conventional E3 ligases or com-
plete dissolution of the sarcomere.
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Secondary Effects of Chronically High Levels of
Circulating IFN-
As in other cell types, IFN- treatment of NRVMs induces
a dramatic increase in immunoproteasome activity, which
has been shown to promote expression of antigenic pep-
tides on major histocompatibility complexes. This up-
regulation augments peptide presentation on both in-
fected and uninfected cells.47,60 It has been suggested
that the structural similarity between viral proteins ex-
pressed in heart tissue during cardiotropic infection and
degraded MyHC peptides could cause inappropriate
recognition of MyHC by the immune system or molecular
mimicry.61 Indeed, the phenotype of mice that overex-
press IFN- is remarkably similar to that of mice that are
immunized with cardiac -myosin.62 In addition, in pa-
tients, the presence of autoimmune antibodies against
sarcomeric proteins is predictive of the development of
DCM.63 IFN-–induced increases in immunoproteasome
activity and MyHC degradation in cardiac myocytes iden-
tified in our studies could promote such an effect.
Conclusions
We show that exposure to the proinflammatory cytokine
IFN- caused atrophy of cardiomyocytes and stimula-
ted the selective degradation of cardiac MyHC protein
in a proteasome-dependent manner. Although specific
components of the constitutive UPS pathway were not
up-regulated, IFN- caused a striking increase in immu-
noproteasome activity in cardiac myocytes. Immunopro-
teasomes have altered cleavage site preferences and
protein cleavage rates to increase antigenic peptide pre-
sentation and therefore may be responsible for the spe-
cific degradation of MyHC in this model. In fact, mice
immunized with cardiac -MyHC peptide fragments de-
velop severe myocarditis,63 implying a potential positive
feedback loop whereby inflammation and high IFN- lev-
els increase MyHC peptide fragment generation, result-
ing in a persistent immune response and further inflam-
mation and IFN- secretion. Although caspases have
been implicated in proteolysis during atrophy by shuttling
proteins to the UPS,64 our data support a caspase-inde-
pendent mechanism of MyHC degradation. Our data may
be extensible to patients who receive IFN- as therapeu-
tics for osteoporosis or chronic granulomatous disease.28
In addition, this in vitro system may be useful as a model
to study the mechanisms responsible for the specific
degradation of MyHC. The data presented here provide
new insights into the molecular mechanisms responsible
for the cardiac phenotypes observed in many inflamma-
tory diseases.
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